Canada markets closed

H-CYTE, Inc. (HCYT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.500.00 (0.00%)
At close: 03:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close5.50
Open5.92
BidN/A x N/A
AskN/A x N/A
Day's Range5.50 - 5.50
52 Week Range2.02 - 77.00
Volume312
Avg. Volume54
Market Cap1.621M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days

    Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset PortfolioTAMPA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company expects to close its acquisition of Jantibody within the next 30 days for an undisclosed amount. Highlights: Milestone achieved as H-CYTE advances plans to build a diverse asset portfolioFocus indication for ovarian cancer with the potential to be use

  • GlobeNewswire

    H-CYTE Announces 1-for-1,000 Reverse Stock Split

    Strategic Decision to Support Improved Investor Profile and Potential Future Uplisting of Securities to Major ExchangeTAMPA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that the Board approved a 1-for-1,000 reverse stock split, effective 9:30 a.m. on Monday, June 13, 2022. The Company’s common stock will open for trading on the OTC Exchange on Monday, June 13, 2022 on a split-adjusted basis under the current trading symbol "H

  • GlobeNewswire

    H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

    Proceeds to Support Inorganic Growth and General Working Capital PurposesTAMPA, Fla., March 04, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that it has received $1,053,605 from the exercise of 75,257,511 previously issued warrants. The funds received will be used to fund the Company’s transition to a hybrid-biopharmaceutical company through strategic acquisitions, as well as for general working capital purposes. In connection with the exerc